Main Article Content
Abstract
Background: Quality by Design is a systematic, science- and risk-based approach to pharmaceutical development that builds product quality into the formulation and process by understanding and controlling the relationships between material attributes, process parameters, and drug product quality attributes, rather than relying exclusively on end-product testing to confirm quality. Established through the ICH Q8, Q9, and Q10 guidelines and endorsed by regulatory agencies globally, QbD has transformed the conceptual framework of pharmaceutical development from empirical trial-and-error to structured knowledge-based design. The integration of artificial intelligence and machine learning with QbD methodology represents the most significant recent evolution of the QbD paradigm, enabling automation of risk assessment, acceleration of design space exploration, real-time prediction of quality attributes from process data, and data-driven continuous improvement of manufacturing processes at a scale and speed that manual QbD implementation cannot achieve.
Objective: This review critically examines the theoretical foundations and practical implementation of Quality by Design in pharmaceutical product development, the integration points between AI and ML methodologies and each component of the QbD framework, the application of AI-augmented QbD in solid oral dosage form development, continuous manufacturing, biological product development, and regulatory submissions, with emphasis on advances through 2024.
Results and Discussion: Bayesian optimization and Gaussian process regression have emerged as the most efficient computational tools for design space exploration within the QbD framework, achieving equivalent or superior design space characterization with 30 to 70% fewer experiments compared to conventional response surface methodology designs. Natural language processing applied to historical batch records, regulatory submissions, and scientific literature enables automated extraction of process knowledge that supports root cause analysis, failure mode identification, and continuous improvement. Large language models trained on pharmaceutical regulatory text demonstrate capability to assist in preparation of QbD sections of Common Technical Documents, reducing documentation burden while maintaining regulatory compliance.
Conclusion: The integration of AI and ML with QbD methodology represents a genuine paradigm shift in pharmaceutical product development, transitioning from structured but manually intensive QbD implementation to intelligent, data-driven continuous learning manufacturing systems. The regulatory acceptance of AI-augmented QbD tools is advancing, with ICH E14 and FDA AI/ML guidance documents establishing frameworks for AI use in pharmaceutical development that align with QbD principles.